Wedescribetheeffects ofiopanoicacid ondaily levelsoffree triiodothyronine( F~) andfreethyroxine(FT) inapatient withprogressivetypeIIamtodarone-induced thyrotoxicosis (AIT) who was undergoing thyroidectomy. The patient wasa 59-year-old man who was undergoing am iodatone therapy while awaiting cardiac transplantation; the use of beta blockers and corticosteroids to controltheAIT was contraindicated in this patient. Prior to thyroidectomy, the patient was started on iopanoic acid at 1.0 g twice a day; in response togastrointestinal side effects, the dosage wassubsequently reduced to0.5 g twice a day. Thepatient responded to iopanoic acid with a rapid decrease in his FT 3 leveland slight increase in his FT 4 level. This control of thyrotoxicosisallowedforan uneventful thyroidectomy, which waslaterfollo wedby successfulcardiactransplantation. Based on ourfindings in this single case, we believe that iopanoiccanbe used torapidly lowerFT 3l eveis and to treatsymptoms of thyrotoxicosis in a preoperativesetting. Wealso discuss thedifferentpharmacodynamic effects that iopanoic acid has on FT and FT levels.
Introduction
Amiodaron e is an iodine-rich dru g th at is used to treat various types of cardi ac disease. In some pati ents, it has been found to induce thyroid disorders significant enough to require thyroidectomy. Thi s is particularly true in cases where the underlying cardiac disease does not allow for the discontinuation of amiodarone. Amiodaron e-induced thyrotoxicosi s (AIT) has lon g posed a challenge to sur geons who attempt to tr eat it with thyroid ectomy in th at th e very entity th at necessitates surgical tr eatm ent represents the primary danger associated with sur gery. Iop anoic acid, a potent 5'-deiodinase inhibitor, is one of several agents used to manage AIT preoperatively, and it is in many respects one of the more well-suited. 1, 2 It rapidl y reduces triiodothyronine (T 3 ) levels, the reby allowing for surgical tr eatment shortly after the induction of th erapy.
AIT is subclassified as type I and type II. Type I AIT occurs in patient s with preexistin g thyroid disease, such as multinodular goiter or Graves disease. Type II AIT occurs in previously euthyroid patients. Mixed forms have also been described. Iodine uptake differs in the two types, as do treatment recommendations. Patient s with type I AIT respond to the increased iodine load presented by am iodarone with an incre ase in hormone production.' Th ese patients often respond to thi on amides, which inhibit th e proc essing of iodine int o thyroid hormone. Patients with type II AIT show decreased iodine uptake and decreased vascularity on Doppler testin g.' Hyperthyroidism in these patients is thought to be caused by th e toxic effects of am iodarone and the direct destruction of thyroid tissue that results in a release of stored hormone. ' Therefore, drugs that inhibit th e organification process are not as successful in type II AlT, and glucocorticoids are more often used.
Iop anoi c acid has been described as a treatment for AIT. Its ability to inh ibit the peripheral conversion of thyroxine (T) to T 3 ma kes it effective in type II as well as type I AlT.While it is not indicated for lon g-term use because it increases T 4 levels, it has been quite helpful as a pr eoperative agent because of its short onset of action. ....
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Discussion
In this patient with type II AIT who was schedu led for thyroidectomy,administration of iopanoic acid resulted in a rapid resolution ofFT 3 elevation and a persistent and even progressive elevation in FT 4 level. These findings are consistent with the mechanism of action of iopanoic acid,which involvesan inhibition of the peripheral conversion of FT 4 to the more active FT 3 by iodothyronine 5'-monodeiodinase. Because iopanoic acid has little effect on the underlying destructive thyroiditis, it is not surprising that the FT 4 level would remain elevated in the setting of conti nued underlying inflam mation and destruction of the thyroid gland with release of stored hormones. Our findings are also consistent with tho se of other studies of FT 4l evels following the initiation of with improvement in the patient's thyrotoxic symptoms. After surge ry, his FT 3le vei dropped below normal and remained there. The patient's FT 4 concentration dipped slightly after the initiation of iopanoic acid, then slowly began to rise as expected , reaching 6.0 pmol/L by the time of thyroidectomy. The level increased transiently to 7.4 pmo l/L on postoperative day2 , then dropped to near-no rmal at 2.0 pmol/L on postoperative day 7, and finally norm alized at 1.4 pmo l/L 2 weeks postoperatively.
Amiodarone infusion was restarted postoperatively, and levothyroxine replacement was initiated once th e FT 4 level dropped to low-norm al values. The patien t underwent successful cardiac transplantation 6 weeks following the thyroidectomy. 
Cl inical Course and Thyroid Hormone Levels
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Case report
The patient was a 59-year-old black man who was awaiting cardiac tra nsplantation for nonischem ic cardiomyopathy. He had a history of atria l fibrillat ion and had been treated with Figure. Graph shows the rise and fall of FT J and FT 4 levels throughout the patient's amiodarone for almost 2 years; beta hospitalization. blockers and corticosteroids had been contraindicated in this patient. He was admitted for control ofatrial fibrillation in the setting of exacerbated congestive heart failure. Upon admission, the patient was discovered to be thyrotoxic. He was transferred to the intensive care unit, where thyroid function testing revealed that his thyroidstimulating hormone (TSH) level was undetectable, his FT3 levelwas high-normal at 3.8 pmol/L (reference range: 2.3 to 4.2), and his FT 4 levei was elevated at 1.9 pmol/L (reference range: 0.9 to 1.8) ( figure) . The amiodarone was disconti nued and thionamide therapy was started. Thyroid ultrason ography detected a hyp ovascular gland witho ut nodul arity. A presumptive diagnosis of type II AIT was made. Steroids were recommended but not prescribed because the cardio logist was concerned about the risk of infection in a patient who was awaiting transplantation and who had experienc ed numerous bouts of sepsis previously.
The patient's FT 3 and FT 4leveis were measured daily throughout his hospitalization (figure). After 2 weeks of thionamide therapy in the intensive care unit, his FT 3levei had risen to 8.8 pmol/L and his FT 4le vei had increased to 4.7 pmol/L, A joint decision was made to proceed with definitive surgical. th erapy. Iopanoic acid therapy was then initi ated at 1.0 g twice daily.Within 24 hours, the patient's FT 3levei had fallen to 4.4 prno l/L, but gastrointestinal side effects dictated a reduction in the dosage to 0.5 g twice daily. Still, within another 24 hou rs, his FT 3 level dropped into normal range at 3.9 prno l/L and remained with in this range for th e next 5 preoperative days. The red uction in FT3 level coincided In this article , we describe the case of a pati ent in whom iopanoic acid was an attractive option for controlling thyrotoxicosis prior to definitive surgical therapy. We discuss the different pharmacodynamic effects that this agent had on daily free triiodothyron ine (FT 3 ) and free thyroxine (FT 4 ) levels in a patient with progressive type II AlT. The continued rise of both the FT 3 and FT 4 levels before the start of iopanoic acid therapy in the setting of thionamide treatment that we observed is also consistent with the mechanism of type II AlT. Because iodine uptake is low in this type of AIT, targeting the organification process with a thionamide would not be expected to have a significant effect.
Finally, the clinical findings of improved symptomatology are consistent with the rapid drop in FT 3 level and the delayed fall in FT 4levels. In a study comparing prednisone with iopanoic acid for type II AIT, Bogazzi et al found that a fall in FT 3 levels correlated with a resolution of symptoms, notwithstanding the persistent elevation of Fl'j levels."
For the long-term management oftype IIAIT,iopanoic acid remains inferior to corticosteroids." The use of iopanoic acid in this setting is limited by recurrence issues, by questions about the implications of clinically silent elevations in FT 4 levels, and by the unhindered progress of thyroid inflammation. Its preoperative use as described here, however, has engendered little opposition. The drug rapidly decreases FT3 levels without major risks, and at least in this case, the dose reduction alleviated side effects without diminishing the drug's efficacy. mimic several other lesions. Histopathologic examination is required to confirm the diagnosis. When IPEH is located in the supraglottic larynx and hypopharynx, as in our patient, the initial symptom might be dysphagia. The treatment of choice for this benign lesion is surgical removal. Recurrence is extremely rare.
